The first-in-class RET kinase inhibitor shows durable responses and favorable progression-free and overall survival rates in the 5-year final analysis of the LIBRETTO-001 trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/selpercatinib-linked-long-term-survival-thyroid-cancer-2025a1000pza?src=rss
Author :
Publish date : 2025-09-29 09:57:00
Copyright for syndicated content belongs to the linked Source.
